MicroRNAs associated with metastatic prostate cancer

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Watahiki, Akira ^a,c   Wang, Yuwei ^a   Morris, James ^a   Dennis, Kristopher ^a   O'Dwyer, Helena M ^a   Gleave, Martin ^b,c   Gout, Peter W ^a,b   Wang, Yuzhuo ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; BIOLOGICAL MARKER; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; RNA SEQUENCE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; NEOPLASM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROSTATE TUMOR;

MUS;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053584635     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024950     Document Type: Article

References (81)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Makarov DV, Loeb S, Getzenberg RH, Partin AW, (2009) Biomarkers for prostate cancer. Annu Rev Med 60: 139-151.
3. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R, (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515-524.
4. Iorio MV, Croce CM, (2009) MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27: 5848-5856.
5. Baranwal S, Alahari SK, (2010) miRNA control of tumor cell invasion and metastasis. Int J Cancer 126: 1283-1290.
6. Gandellini P, Folini M, Zaffaroni N, (2010) Emerging role of microRNAs in prostate cancer: implications for personalized medicine. Discov Med 9: 212-218.
7. Sharpless NE, Depinho RA, (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5: 741-754.
8. Fidler IJ, (2002) Critical determinants of metastasis. Semin Cancer Biol 12: 89-96.
9. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, et al. (2005) An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 85: 1392-1404.
10. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, et al. (2005) Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 96: 48-55.
11. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, et al. (2006) Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res 12: 4043-4054.
12. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, et al. (2005) Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 64: 149-159.
13. Lin D, Watahiki A, Bayani J, Zhang F, Liu L, et al. (2008) ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res 68: 4352-4359.
14. Zhao J, Grant SF, (2011) Advances in Whole Genome Sequencing Technology. Curr Pharm Biotechnol 12: 293-305.
15. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, et al. (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17: 535-546.
16. Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, et al. (2008) Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 18: 610-621.
17. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, et al. (2010) The UCSC Genome Browser database: update 2011. Nucleic Acids Res 39: D876-82.
18. Hackenberg M, Sturm M, Langenberger D, Falcon-Perez JM, Aransay AM, (2009) miRanalyzer: a microRNA detection and analysis tool for next-generation sequencing experiments. Nucleic Acids Res 37: W68-76.
19. Wang X, (2008) miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 14: 1012-1017.
20. Wang X, El Naqa IM, (2008) Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24: 325-332.
21. Cheadle C, Vawter MP, Freed WJ, Becker KG, (2003) Analysis of microarray data using Z score transformation. J Mol Diagn 5: 73-81.
22. Jiang P, Wu H, Wang W, Ma W, Sun X, et al. (2007) MiPred: classification of real and pseudo microRNA precursors using random forest prediction model with combined features. Nucleic Acids Res 35: W339-344.
23. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, et al. (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135.
24. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, et al. (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176.
25. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, et al. (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181-187.
26. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
27. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, et al. (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16: 206-216.
28. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, et al. (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8: 529-538.
29. Ozen M, Creighton CJ, Ozdemir M, Ittmann M, (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793.
30. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170.
31. Gandellini P, Folini M, Zaffaroni N, (2009) Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol Med 15: 381-390.
32. Manzur M, Fleming P, Huang DC, Degli-Esposti MA, Andoniou CE, (2009) Virally mediated inhibition of Bax in leukocytes promotes dissemination of murine cytomegalovirus. Cell Death Differ 16: 312-320.
33. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215.
34. Musiyenko A, Bitko V, Barik S, (2008) Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med 86: 313-322.
35. Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, et al. (2009) Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol 2009 Apr 15. [Epub ahead of print].
36. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, et al. (2009) miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 69: 2287-2295.
37. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, et al. (2010) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127: 394-403.
38. Shi XB, Xue L, Yang J, Ma AH, Zhao J, et al. (2007) An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 104: 19983-19988.
39. Lee YS, Kim HK, Chung S, Kim KS, Dutta A, (2005) Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem 280: 16635-16641.
40. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, et al. (2011) miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 71: 538-549.
41. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ, (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-158.
42. Fu H, Hu Z, Wen J, Wang K, Liu Y, (2009) TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin (Shanghai) 41: 648-656.
43. Kusters B, Kats G, Roodink I, Verrijp K, Wesseling P, et al. (2007) Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. Oncogene 26: 5808-5815.
44. Sato T, Oshima T, Yoshihara K, Yamamoto N, Yamada R, et al. (2009) Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncol Rep 21: 211-216.
45. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, et al. (2009) ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 23: 1882-1894.
46. Zhang J, Patel L, Pienta KJ, (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21: 41-48.
47. Sethi S, Macoska J, Chen W, Sarkar FH, (2010) Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 3: 90-99.
48. Chu CY, Chang CC, Prakash E, Kuo ML, (2008) Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci 15: 675-685.
49. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, et al. (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446: 690-694.
50. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, et al. (2011) Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts. Clin Cancer Res 17: 783-791.
51. Karlou M, Tzelepi V, Efstathiou E, (2010) Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 7: 494-509.
52. Bogner PN, Patnaik SK, Pitoniak R, Kannisto E, Repasky E, et al. (2009) Lung cancer xenografting alters microRNA profile but not immunophenotype. Biochem Biophys Res Commun 386: 305-310.
53. Murata T, Takayama K, Katayama S, Urano T, Horie-Inoue K, et al. (2010) miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 13: 356-361.
54. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, et al. (2009) Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 379: 726-731.
55. Zhang J, Guo H, Zhang H, Wang H, Qian G, et al. (2011) Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene. Cancer 117: 86-95.
56. Gotte M, Mohr C, Koo CY, Stock C, Vaske AK, et al. (2010) miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 29: 6569-6580.
57. Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, et al. (2011) Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30: 619-630.
58. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, et al. (2009) miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27: 1712-1721.
59. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, et al. (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28: 1714-1724.
60. Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, et al. (2010) MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 29: 4971-4979.
61. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, et al. (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219: 214-221.
62. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, et al. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152.
63. Hurst DR, Edmonds MD, Welch DR, (2009) Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 69: 7495-7498.
64. Khew-Goodall Y, Goodall GJ, (2010) Myc-modulated miR-9 makes more metastases. Nat Cell Biol 12: 209-211.
65. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, et al. (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256.
66. Ding J, Huang S, Wu S, Zhao Y, Liang L, et al. (2010) Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol 12: 390-399.
67. Cottonham CL, Kaneko S, Xu L, (2010) miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 285: 35293-35302.
68. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T, (1998) Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153: 141-148.
69. Khvorova A, Reynolds A, Jayasena SD, (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216.
70. Murchison EP, Hannon GJ, (2004) miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr Opin Cell Biol 16: 223-229.
71. Tsang WP, Kwok TT, (2009) The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 30: 953-959.
72. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, et al. (2010) hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 70: 1916-1924.
73. Fernandez-Valverde SL, Taft RJ, Mattick JS, (2010) Dynamic isomiR regulation in Drosophila development. RNA 16: 1881-1888.
74. Lee LW, Zhang S, Etheridge A, Ma L, Martin D, et al. (2010) Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 16: 2170-2180.
75. Ebert MS, Neilson JR, Sharp PA, (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4: 721-726.
76. Qin W, Shi Y, Zhao B, Yao C, Jin L, et al. (2010) miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One 5: e9429.
77. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, et al. (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
78. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, et al. (2010) microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9 2010 Mar 18;9 (6) [Epub ahead of print].
79. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, et al. (2009) Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 69: 1279-1283.
80. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ, (2009) miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 284: 24696-24704.
81. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, et al. (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046.